Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (12901)	12/31/1997 9:18:00 PM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

Andy, I strongly suspect that LGD1550 will have applications for head and neck tumors, but the retinoid discussed on television may in fact be oral Targretin. It's Phase I trial, initiated in 1994 was on head and neck and it is also in advanced prostate trials. The Washington DC report was on head and neck tumors (tongue and mouth) and the patient interviewed has been treated three years ealier (before LGD1550's IND): Message 2786540 I suspect that the recent reports are on Targretin. Of course LGD1550 results were "better than we could have hoped for" according to SA, so it is possible that similar dramatic results are being seen with head and neck patients who are enrolled in ALRT1550's Phase I trial, but I'm guessing that they are talking about oral Targretin.